Comparative Pharmacology
Head-to-head clinical analysis: EMTRIVA versus LAMIVUDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRIVA versus LAMIVUDINE.
EMTRIVA vs LAMIVUDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; emtricitabine is phosphorylated to emtricitabine 5'-triphosphate which competes with deoxycytidine 5'-triphosphate for incorporation into viral DNA, resulting in chain termination.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV reverse transcriptase and hepatitis B virus polymerase via incorporation into viral DNA, causing chain termination.
Emtricitabine 200 mg orally once daily.
150 mg orally twice daily or 300 mg orally once daily; for HIV-1 infection, 300 mg once daily or 150 mg twice daily; for hepatitis B, 100 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateLamivudine + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Lamivudine."
Clinical Note
moderateLamivudine + Ranolazine
"The serum concentration of Ranolazine can be increased when it is combined with Lamivudine."
Clinical Note
moderateLamivudine + Bupropion
"The serum concentration of Bupropion can be increased when it is combined with Lamivudine."
Clinical Note
moderateLamivudine + Rolapitant
Terminal elimination half-life ~10 hours (mean 10 h, range 7-14 h) in adults; prolonged in renal impairment (up to 90 h in severe impairment)
Terminal elimination half-life: 5-7 hours in adults; prolonged to 20-35 hours in patients with creatinine clearance <30 mL/min, necessitating dose adjustment
Renal excretion of unchanged drug (~86%) by glomerular filtration and active tubular secretion; fecal excretion (<1%)
Renal: approximately 70% of the dose excreted unchanged in urine via glomerular filtration and active tubular secretion; biliary/fecal: minimal, less than 5%
Category C
Category A/B
Antiretroviral, NRTI
NRTI
"The serum concentration of Rolapitant can be increased when it is combined with Lamivudine."